JP Morgan Rates Bajaj Finance Neutral; Targets Rs 1,040
JP Morgan has issued a neutral rating for Bajaj Finance, establishing a target price of Rs 1,040. The analysis emphasizes the company’s strategic vision to attain a credit market share of 3.2-3.5% and a retail credit market share of 3.6-4% by FY30, up from the current 2.8%. Furthermore, Bajaj Finance intends to improve product penetration, which is anticipated to significantly boost disbursements and assets under management (AUM).
Bajaj Finance’s Growth Strategy
Bajaj Finance is committed to increasing its market share in the credit sector. Analysts from JP Morgan underscore that the company aspires to elevate its total credit market share to between 3.2% and 3.5% by FY30. Currently, it holds a 2.8% stake. To reach this target, Bajaj Finance plans to enhance product penetration, aiming to raise products per customer from 6.05 to a range of 6.5 to 7.5. This strategy is projected to deliver numerous advantages, including substantial growth in disbursements and AUM. The midpoint of the company’s FY30 guidance implies a compounded annual growth rate (CAGR) of 21.6% for AUM and 23.9% for net profit from FY26 to FY30. This follows a remarkable performance over the last 18 years, where the company achieved a 35% CAGR in AUM and a 48% CAGR in net profit. However, analysts caution that the current elevated valuations of the stock may restrict its upside potential.
Biocon’s Strategic Integration
Goldman Sachs has assigned a neutral rating to Biocon, with a target price of Rs 375. This assessment follows Biocon’s announcement regarding its plans to integrate with Biocon Biologics, its subsidiary. The company believes this integration will yield a more streamlined corporate structure, potentially eliminating the HoldCo discount. Moreover, the merger is anticipated to generate a consolidated balance sheet with enhanced financial metrics and operational synergies stemming from the amalgamation of resources, including commercial and manufacturing infrastructure. The integration seeks to fortify Biocon’s global stance, particularly in critical therapeutic areas such as diabetes, oncology, and immunology.
Tata Capital’s Growth Prospects
Kotak Institutional Equities has initiated coverage on Tata Capital, awarding it an “add” rating with a target price of Rs 360. Tata Capital stands as India’s third-largest non-banking financial company (NBFC), boasting a loan book of Rs 2.44 lakh crore as of the end of September 2023. The company’s well-diversified portfolio predominantly focuses on retail lending, which accounts for 61% of its loan book. Analysts forecast that Tata Capital’s recent expansions will likely foster a 21% CAGR in gross loans from FY25 to FY28. The turnaround of the recently merged TMFL’s loss-making operations, along with improving leverage, is expected to contribute positively to earnings per share (EPS) growth.
Suzlon Energy’s Market Position
Morgan Stanley has assigned an overweight rating to Suzlon Energy, setting a target price of Rs 78. Analysts predict that India’s wind energy additions will exceed the 2030 target of 100GW, with an additional 20-30GW potential from the commercial and industrial (C&I) segment. Key factors propelling this growth include a significant pipeline of projects currently under construction, an uptick in intra-state bids, and rising demand from the C&I sector. Presently, 40GW worth of projects are in execution, with about 25GW yet to be ordered. The reduction of inter-state transmission system waivers is anticipated to encourage more intra-state bids, which typically encounter fewer delays due to lower capacity constraints and fewer right-of-way issues.
Digihunt is not a financial advisor and this is not investment advice.
